LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Overview:
The LATAM women hypoactive sexual desire disorder treatment market accounted for $131 million in 2019, and is expected to reach $170 million by 2027, registering a CAGR of 3.8% from 2020 to 2027.
Hyposexual desire disorder (HSDD) in women is defined as deficiency or lack of sexual fantasies and desire of sexual activity. Furthermore, HSDD is a highly prevalent sexual desire disorder in women, which can severely impact the quality of life of a patient. Thus, treatment is required, which involves use of certain drugs such as bupropion, buspirone, bremelanotide, and flibanserin. These drugs have varying mechanism of action on HSDD. For instance, the FDA approved treatment bremelanotide works by lowering serotonin levels in brain and increasing norepinephrine and dopamine neurotransmitters. Furthermore, women hypoactive sexual desire disorder treatments are available in hospitals, clinics, and through online retailers.
The factors that contribute to LATAM women hypoactive sexual desire disorder treatment market growth include rise in prevalence of lifestyle ailments, such as stress, depression, anxiety, and prolonged fatigue, and rise in use of medicines, which induces state of hypoactive sexual desire disorder. For instance, stress can lead to release of hormones such as cortisol and epinephrine. These hormones in high levels can lead to diminished sex drive. Similarly, depression is marked by depressed mood, decreased energy, and loss of interest in pleasurable activities. In addition, rise in number of surgical procedures, which lead to sexual dysfunction, are expected to boost LATAM women hypoactive sexual desire disorder treatment market growth during the forecast period. However, lack in awareness related to hypoactive sexual desire disorder are anticipated to hamper the market growth during the forecast period. For instance, there is a lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana. This contributes to low diagnosis of HSDD in these countries. Moreover, presence of strong pipeline products, which are in their late phases of clinical trials are expected to get approved for commercialization in coming years. Hence, presence of pipeline drugs offer a lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market.
COVID-19 Impact Analysis on LATAM women hypoactive sexual desire disorder treatment market
COVID-19 pandemic has affected every business adversely. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This led to disruption, limitation, challenges, and changes in each sector of every industry in Latin America. Similarly, COVID-19 impacted off label generic HSDD treatments in a negative manner. This was attributed to the fact that initial breakout of the virus led to strict lockdowns throughout the world, which, in turn, led to a decline in logistic services Furthermore, the healthcare system during the pandemic became more focused on providing care to COVID-19 patients. This led to rescheduling of doctor appointments, which were of elective nature. Thus, demand for HSDD drugs during the initial period of pandemic is estimated to have suffered a decline. However, as the situation around pandemic is gradually becoming better, the supply is expected to be restored.
Latam Women Hypoactive Sexual Desire Disorder Treatment Market Segmentation
The LATAM women hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, sales channel, and country. By treatment type, the market is categorized into buspirone and bupropion. On the basis of sales channel, it is divided into hospitals, clinics, and online retailers. Country wise, the LATAM women hypoactive sexual desire disorder treatment market size is studied across Brazil, Argentina, Chile, Colombia, Ecuador, Peru, and rest of the LATAM.
Segment Review
By type, the LATAM hypoactive sexual desire disorder treatment market is segmented into buspirone and bupropion. The buspirone segment is expected to exhibit fastest growth rate during the forecast period, owing to the fact that it is FDA approved treatment aimed at HSDD in premenopausal women, which makes it a preferred brand over the off label treatments. Furthermore, this treatment type has lesser side effects as compared to other treatment options present in the market.
By Treatment Type
Bupropion segment is projected as one of the most lucrative segment.
By sales channel, the hospitals segment occupied the major LATAM women hypoactive sexual desire disorder treatment market share in 2019, owing to the fact that the treatment of HSDD requires specialist availability in hospitals. In addition, the clinics segment is expected to witness highest growth rate during the forecast period, owing to rise in awareness related to diagnosis and treatment of HSDD, which is expected to contribute toward surge in number of clinics providing such services.
By Sales Channel
Hospitals segment held a dominant position in 2019 and will continue to maintain the lead over the forecast period.
Country wise, Argentina is expected to exhibit the fastest growth during the forecast period. This is attributed to factors such as rise in healthcare infrastructure, surge in healthcare expenditure, and rise in awareness related to hypoactive sexual desire disorder. In addition, Rest of LATAM acquired the major share of LATAM women hypoactive sexual desire disorder treatment market size, owing to the presence of large patient base.
By Country
Argentina would exhibit the highest CAGR of 5.2% during 2020-2027.
The LATAM women hypoactive sexual desire disorder treatment market is highly competitive and prominent players in the market have adopted various strategies to garner maximum LATAM women hypoactive sexual desire disorder treatment market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Aurobindo Pharma, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Mylan N.V., Novartis AG, Palatin Technologies, Inc., Sprout Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila.
Key Benefits For Stakeholders
- This report entails a detailed quantitative analysis along with the current LATAM women hypoactive sexual desire disorder treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
- The LATAM women hypoactive sexual desire disorder treatment market forecast is studied from 2020 to 2027.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the LATAM women hypoactive sexual desire disorder treatment market.
LATAM Women Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Report Highlights
| Aspects | Details |
 By Treatment Type |
|
 By Sales Channel |
|
 By Country |
|
 Key Market Players | ZYDUS CADILA, SUN PHARMACEUTICAL INDUSTRIES LIMITED, MYLAN N.V., AUROBINDO PHARMA, PALATIN TECHNOLOGIES, INC., SPROUT PHARMACEUTICALS, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS), NOVARTIS INTERNATIONAL AG, GLAXOSMITHKLINE PLC (GSK), BRISTOL-MYERS SQUIBB COMPANY |
Analyst Review
The use of women hypoactive sexual desire disorder (HSDD) treatment products are anticipated to witness a significant growth, owing to rise in use of medicines that induce the state of hypoactive sexual desire disorder, and increase in number of surgical procedures which lead to sexual dysfunction. In addition, increase in prevalence of hypoactive sexual desire disorder has led to surge in demand for new treatment options, which is expected to drive the market growth during the forecast period.
Presence of pipeline drugs offers lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market. Major factors that hinder growth of the market include lack of awareness related to hypoactive sexual desire disorder, which leads to limited diagnosis and treatment. For instance, there is lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana.
Medical care given to a women suffering from hypoactive sexual desire disorder is termed as hypoactive sexual desrie disorder treatment. Furthermore, the treatment includes use of various drugs such as buspirone, bupropion and others.
Hypoactive sexual desire disorder treatments include different kinds of drugs which work through different mechanisms to increase the low sexual desire in women.
Argentina has the highest growth rate in the market with a CAGR of 5.2%. This is due to rise in healthcare expenditure in the region and surge in awareness related to treatment of hypoactive sexual desire disorder.
The total market value of LATAM women hypoactive sexual desire disorder treatment market is $130.68 million in 2019.
The forecast period for LATAM women hypoactive sexual desire disorder treatment market is 2020 to 2027
The market value of LATAM women hypoactive sexual desire disorder treatment market in 2020 is $130.81 million.
The base year is 2019 in LATAM women hypoactive sexual desire disorder treatment market
Top companies such as, GlaxoSmithKline plc, Bristol Myers Squibb, Mylan N.V., Palatin Technologies, Inc., and Sprout Pharmaceuticals, Inc held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
Bupropion segment is the most influencing segment as this medications is FDA approved for use in HSDD in women. Furthermore, the product has lesser side effects related to other options available in the market.
The major factor that fuels the growth of the LATAM women hypoactive sexual desire disorder treatment market includes rise in prevalence of lifestyle ailments such as stress, depression which can contribute to development of hypoactive sexual desire disorder in women.
Loading Table Of Content...
